Hong Kong News

Nonpartisan, Noncommercial, unconstrained.
Sunday, Jan 29, 2023

Domestic COVID-19 drug effective in trial

Domestic COVID-19 drug effective in trial

Listen to the article
0:00
0:00
A domestic antiviral COVID-19 pill is as effective at alleviating symptoms as Paxlovid — one of the most widely used treatments for the virus globally, according to a study published in China on Wednesday.
In a clinical trial involving 822 people in Shanghai from March to May, patients taking VV116 — the homegrown oral pill — recovered after a median of four days, compared with five days for those on Paxlovid, according to the study published in The New England Journal of Medicine, a peer-reviewed international journal.

No trial participants had died or developed more severe symptoms by the 28th day after treatment started, it said, adding that about three-quarters had been vaccinated.

The incidence of adverse events was lower in the group taking VV116 than those taking Paxlovid, according to the study.

"Among adults with mild to moderate COVID-19 who were at risk for progression, VV116 was non-inferior to Paxlovid with respect to the time to sustained clinical recovery, with fewer safety concerns," said the study.

The trial is China's first test of a domestic COVID-19 pill during the Omicron-driven outbreaks. It was carried out by a number of researchers and doctors based in Shanghai.

VV116 is being developed by domestic drugmaker Junshi Biosciences and Vigonvita Life Science, as well as researchers from the Chinese Academy of Sciences.

Ding Jian, a senior researcher at Shanghai Institute of Materia Medica of Chinese Academy of Sciences, said that the antiviral pill is an important weapon in the arsenal against the virus. As China has adjusted its COVID-19 control measures, more effort should be devoted to developing, producing and stockpiling antiviral therapeutics.

"Oral COVID-19 pills have several advantages, such as being easy to deliver and access. They are expected to play a vital role in disease control efforts," he said.

Junshi Biosciences said that it began advancing clinical trials and production of VV116 in October last year. On Dec 31, 2021, the drug gained its first emergency use authorization from health authorities in Uzbekistan.

So far, two COVID-19 treatments are available on the mainland.

In February, the National Medical Products Administration granted emergency use authorization to Pfizer's Paxlovid. "However, supply falls short of the global demand, which creates a need for more options," said the study.

In July, the administration issued conditional approval to Azvudine, a domestically developed drug, to be used to treat adult COVID-19 patients with moderate symptoms. The medication was previously approved as an HIV/AIDS drug in July of last year.
Newsletter

Related Articles

Hong Kong News
Close
0:00
0:00
China is opening up for foreign investors.
Tesla reported record profits and record revenues for 2022
Prince Andrew and Virginia Giuffre Photo Is Fake: Ghislaine Maxwell
Moonwalker Buzz Aldrin Gets Married On His 93rd Birthday
Federal Reserve Probes Goldman’s Consumer Business
China's first population drop in six decades
Microsoft is finalising plans to become the latest technology giant to reduce its workforce during a global economic slowdown
China's foreign ministry branch in Hong Kong urges British gov't to stop the biased and double standards Hong Kong report
China relaxes 'red lines' on property sector borrowing in policy pivot
Tesla slashes prices globally by as much as 20 percent
Japan prosecutors indict man for ex-PM Shinzo Abe murder
Vietnam removes two deputy PMs amid anti-corruption campaign
1.4 Million Copies Of Prince Harry's Memoir 'Spare' Sold On 1st Day In UK
After Failing To Pay Office Rent, Twitter May Sell User Names
FIFA president questioned by prosecutors
Britain's Sunak breaks silence and admits using private healthcare
Hype and backlash as Harry's memoir goes on sale. Unnamed royal source says prince 'kidnapped by cult of psychotherapy and Meghan'
China’s recovery could add 1% to Australia’s GDP: JPMorgan 
Saudi Arabia set to overtake India as fastest-growing major economy this year 
China vows to strengthen financial support for enterprises: official
International medical experts speak out against COVID-19 restrictions on China
2 Billion People To Travel In China's "Great Migration" Over Next 40 Days
Google and Facebook’s dominance in digital ads challenged by rapid ascent of Amazon and TikTok
Flight constraints expected to weigh on China travel rebound
Billionaire Jack Ma relinquishes control of Ant Group
FTX fraud investigators are digging deeper into Sam Bankman-Fried's inner circle – and reportedly have ex-engineer Nishad Singh in their sights
Teslas now over 40% cheaper in China than US
TikTok CEO Plans to Meet European Union Regulators
UK chaos: Hong Kong emigrants duped by false prospectus
China seeks course correction in US ties but will fight ‘all forms of hegemony’, top diplomat Wang Yi says
China will boost spending in 2023
African traders welcome end of China’s Covid travel curbs
France has banned the online sale of paracetamol until February, citing ongoing supply issues
Japan reportedly to give families 1 million yen per child to move out of Tokyo
Will Canada ever become a real democracy?
Hong Kong property brokerages slash payrolls in choppy market
U.S. Moves to Seize Robinhood Shares, Silvergate Accounts Tied to FTX
Effect of EU sanctions on Moscow is ‘less than zero’ – Belgian MEP
Coinbase to Pay $100 Million in Settlement With New York Regulator
Preparations begin for Spring Festival travel rush
Domestic COVID-19 drug effective in trial
HK to see a full recovery, John Lee says in New Year message
Bargain hunters flock to last day of Hong Kong brands and products expo
Hong Kong aims for January 8 reopening of border with mainland China
Chinese Revenge Travelers Will Steer Clear of a Hostile US
FTX assets worth $3.5bn held by Bahamas securities regulator
2023 Will Be the Year of the Electric SUV
A Republican congressman-elect is under investigation in New York after he admitted he lied about his education and work experience.
Brazilian football legend Pele, arguably the greatest player ever, has died at the age of 82.
Hong Kong to scrap almost all its Covid rules
×